Table 1.
Chronic hypoxia, maturation, and potency of bradykinin-induced relaxation
| Normoxia |
Hypoxia |
|||
|---|---|---|---|---|
| Fetus | Newborn | Fetus | Newborn | |
| Control | −6.86 ± 0.21 (14) | −7.89 ± 0.16* (6) | −6.95 ± 0.15 (14) | −7.91 ± 0.12* (16) |
| l-NAME | −6.93 ± 1.09 (5) | −8.43 ± 0.26 (4) | −6.83 ± 0.53 (6) | −7.61 ± 0.43 (7) |
| Indo | −6.38 ± 0.78 (5) | −7.89 ± 0.15 (4) | −6.87 ± 0.74 (3) | −7.04 ± 0.38 (4) |
| ODQ | −6.89 ± 0.84 (4) | −7.89 ± 0.36 (3) | −6.51 ± 0.51 (3) | −7.86 ± 0.67 (4) |
| TEA | −6.44 ± 0.90 (5) | −7.65 ± 0.24 (4) | −7.05 ± 0.32 (3) | −7.68 ± 0.23 (4) |
Values (means ± SE) are shown as log concentration for the IC50 for bradykinin-induced relaxation for data presented graphically in Figs. 2, 5–7, and 9; number of animals is shown in parentheses. l-NAME, NG-nitro-l-arginine methyl ester; Indo, indomethacin; ODQ, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; TEA, tetraethylammonium. Statistical significance as shown using a 95% confidence interval based on the log (inhibitor) vs. response curve fit to the data:
*
significant leftward shift compared with Fetus on the basis of control traces in Fig. 2.